Cargando…
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for subcutaneous (SC) self-administration at monthly doses of 2...
Autores principales: | Hauser, Stephen L., Kappos, Ludwig, Bar-Or, Amit, Wiendl, Heinz, Paling, David, Williams, Mitzi, Gold, Ralf, Chan, Andrew, Milo, Ron, Das Gupta, Ayan, Karlsson, Goeril, Sullivan, Roseanne, Graham, Gordon, Merschhemke, Martin, Häring, Dieter A., Vermersch, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444716/ https://www.ncbi.nlm.nih.gov/pubmed/37450172 http://dx.doi.org/10.1007/s40120-023-00518-0 |
Ejemplares similares
-
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
por: Hauser, Stephen L, et al.
Publicado: (2023) -
Safety experience with continued exposure to ofatumumab in patients
with relapsing forms of multiple sclerosis for up to 3.5 years
por: Hauser, Stephen L, et al.
Publicado: (2022) -
Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
por: Kramer, John, et al.
Publicado: (2023) -
Efficacy and safety of ofatumumab in recently diagnosed,
treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and
II
por: Gärtner, Jutta, et al.
Publicado: (2022) -
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study
por: Bar-Or, Amit, et al.
Publicado: (2021)